Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Depreciation & Amortization (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Accumulated Depreciation & Amortization data on record, last reported at $298.3 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization rose 923.96% year-over-year to $298.3 million; the TTM value through Sep 2025 reached $298.3 million, up 923.96%, while the annual FY2024 figure was $271.6 million, 955.24% up from the prior year.
  • Accumulated Depreciation & Amortization reached $298.3 million in Q3 2025 per AMPH's latest filing, up from $290.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $298.3 million in Q3 2025 and bottomed at $2.5 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $56.0 million, with a median of $9.7 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 55.14% in 2022, then soared 2902.08% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $10.2 million in 2021, then grew by 23.2% to $12.6 million in 2022, then skyrocketed by 104.31% to $25.7 million in 2023, then surged by 955.24% to $271.6 million in 2024, then grew by 9.83% to $298.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $298.3 million in Q3 2025, $290.5 million in Q2 2025, and $271.6 million in Q4 2024.